Skip to content

Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement

Efficacy Study of Oral Collagen Peptide on Skin Conditions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06847035
Enrollment
90
Registered
2025-02-26
Start date
2024-07-25
Completion date
2024-11-19
Last updated
2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Aging

Brief summary

To assess if oral intake of collagen peptide can improve skin conditions such as skin thickness, density and firmness.

Detailed description

This is an one site, randomized, double-blind controlled clinical trial to assess the oral supplement of LISAVEI collagen peptide solid beverage on skin ageing improvement. Study product with collagen peptide and placebo product without collagen were randomly assigned to 90 eligible participants enrolled according to the inclusion and exclusion criteria. They took the assigned product once daily dissolved in 100 ml warm water for 12 weeks with 4-week regression phase(without intake of the test products), and visit the study site in Shanghai for four times(before starting the treatment, after 8 and 12 weeks, and 4 weeks after the last intake). Skin measurements including skin firmness, skin density, skin hydration and skin barrier were carried out at each visit with professional equipment and imaging system. Data were analyzed to validate if the administration of the test collagen peptide solid beverage will improve skin aging parameters such as firmness, thickness, density, hydration and skin barrier compared to placebo. The lasting effect was also observed by comparing between the two groups after 4-week regression time.

Interventions

DIETARY_SUPPLEMENTActive Comparator

LISAVEI collagen peptide solid beverage ( contain 5 g collagen peptide),once daily for 12 weeks

DIETARY_SUPPLEMENTPlacebo Comparator

placebo solid beverage (Maltodextrin with edible flavor),once daily for 12 weeks

Sponsors

Shanghai Meifute Biotechnology Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. Healthy female adults aged between 35-55 years old 2. With fine wrinkles and skin laxity 3. Personal informed consents to participate in the study 4. Agree to keep their daily skincare routine unchanged for the duration of the study 5. Maintain good sun protection habits 5\. Agree to refrain from wearing make-up on the face on the each study visit

Exclusion criteria

1. Female who is pregnant or nursing or planning to become pregnant during the course of the study 2. Individuals who are in the perimenopausal stage. 3. BMI\<18.5 or BMI \>27.9 4. Individuals suffering from chronic systemic diseases such as cardiovascular, cerebrovascular, liver, and kidney diseases. 5. Individuals who have diabetes. 6. Individuals suffering from skin conditions such as psoriasis, eczema, atopic dermatitis, and severe acne. 7. Individuals with depression or sleep disorders, those who smoke, and those who abuse alcohol. 8. Individuals who are using hormonal drugs, medications for obesity, absorption inhibitors, antidepressants, or appetite suppressants. 9. Individuals who have used hormones or anti-inflammatory drugs on their face and upper arms within the past two months. 10. Individuals who received facial laser therapy, chemical peeling or UV overexposure in the past 3 months 11. Individuals who can not avoid prolonged exposure to sunlight. 12. Individuals who are currently participating in other clinical studies or trials.

Design outcomes

Primary

MeasureTime frameDescription
Skin firmnessbefore product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)The changes of skin firmness parameter tested by Cutometer MPA580
Skin thicknessbefore product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)The changes of skin thickness (μm) tested by Ultrascan UC 22
Skin densitybefore product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)The changes of skin density tested by Ultrascan UC 22

Secondary

MeasureTime frameDescription
Skin hydrationbefore product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)The changes of skin hydration tested by Corneometer CM825
Skin barrierbefore product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)The changes of Trans Epidermal Water Loss (skin barrier parameter) tested by Tewameter TM300
Facial imagebefore product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)Photo documents of left, right and frontal facial views

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026